Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors

Neuropsychopharmacology

Volumn 35, Issue 11, 2010, Pages 2155-2164

  Housden, Charlotte R ^a   O'Sullivan, Sean S ^b   Joyce, Eileen M ^c   Lees, Andrew J ^b   Roiser, Jonathan P ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

delay discounting; dopamine agonist; impulsive compulsive spectrum behaviors (ICBs); impulsivity; Parkinson's disease (PD); reward learning

Indexed keywords

AGED; ARTICLE; CLINICAL ARTICLE; COMPULSION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; IMPULSIVE COMPULSIVE BEHAVIOR; IMPULSIVENESS; LEARNING; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROBABILITY; REINFORCEMENT; REWARD LEARNING; STIMULUS;

AGED; COMPULSIVE BEHAVIOR; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; LEARNING; MALE; MIDDLE AGED; PARKINSON DISEASE; QUESTIONNAIRES; REWARD; TIME FACTORS;

EID: 78651293977     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.84     Document Type: Article

References (80)

1. Beck AT, Epstein N, Brown G, Steer RA (1988). An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893-897.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neuro-chemical correlations. J Neurol Sci 20: 415-455.
3. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309-369.
4. Bodi N, Keri S, Nagy H, Moustafa A, Myers CE, Daw N et al (2009). Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dop-amine agonists on young Parkinson's patients. Brain 132: 2385-2395.
5. Boettiger CA, Mitchell JM, Tavares VC, Robertson M, Joslyn G, D'Esposito M et al (2007). Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyl-transferase 158(Val/Val) genotype. J Neurosci 27: 14383-14391.
6. Brown RG, Marsden CD (1988). 'Subcortical dementia': the neuropsychological evidence. Neuroscience 25: 363-387.
7. Cardinal RN, Pennicott DR, Sugathapala CL, Robbins TW, Everitt BJ (2001). Impulsive choice induced in rats by lesions of the nucleus accumbens core. Science 292: 2499-2501.
8. Cardinal RN, Robbins TW, Everitt BJ (2000). The effects of d-amphetamine, chlordiazepoxide, alpha-flupenthixol and behavioural manipulations on choice of signalled and unsignalled delayed reinforcement in rats. Psychopharmacology (Berl) 152: 362-375.
9. Cardinal RN, Winstanley CA, Robbins TW, Everitt BJ (2004). Limbic corticostriatal systems and delayed reinforcement. Ann NY Acad Sci 1021: 33-50.
10. Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L, Robbins TW et al (2007). Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 62: 977-984.
11. Chamberlain SR, Hampshire A, Muller U, Rubia K, Del Campo N, Craig K et al (2009). Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65: 550-555.
12. Chamberlain SR, Sahakian BJ (2007). The neuropsychiatry of impulsivity. Curr Opin Psychiatry 20: 255-261.
13. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC (1994). Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 103: 171-183.
14. Cools R (2006). Dopaminergic modulation of cognitive function- implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 30: 1-23.
15. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV (1991). Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 114(Part 5): 2095-2122.
16. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B (2002). Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 40: 2257-2267.
17. Dubois B, Pillon B (1997). Cognitive deficits in Parkinson's disease. J Neurol 244: 2-8.
18. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD et al (2004). Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19: 397-405.
19. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M et al (2006). Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59: 852-858.
20. Evenden JL (1999). Varieties of impulsivity. Psychopharmacology (Berl) 146: 348-361.
21. Fearnley JM, Lees AJ (1991). Ageing and Parkinson's disease: sub-stantia nigra regional selectivity. Brain 114(Part 5): 2283-2301.
22. Floresco SB, Phillips AG (2001). Delay-dependent modulation of memory retrieval by infusion of a dopamine D1 agonist into the rat medial prefrontal cortex. Behav Neurosci 115: 934-939.
23. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
24. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A (2007). Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22: 1757-1763.
25. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ (2000). Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68: 423-428.
26. Green L, Myerson J (2004). A discounting framework for choice with delayed and probabilistic rewards. Psychol Bull 130: 769-792. (Pubitemid 39216582)
27. Herrnstein RJ (1970). On the law of effect. J Exp Anal Behav 13: 243-266.
28. Hoehn MM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
29. Holden C (2001). 'Behavioral' addictions: do they exist? Science 294: 980-982.
30. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, Antonini A (2008). The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 23: 411-415.
31. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B et al (2006). Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29: 409-416.
32. Kapur S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160: 13-23.
33. Kirby KN, Petry NM, Bickel WK (1999). Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 128: 78-87.
34. Knutson B, Bjork JM, Fong GW, Hommer D, Mattay VS, Weinberger DR (2004). Amphetamine modulates human incentive processing. Neuron 43: 261-269.
35. Lawrence AD, Evans AH, Lees AJ (2003). Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2: 595-604.
36. Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ et al (2010). Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 16: 202-207.
37. Lees AJ, Hardy J, Revesz T (2009). Parkinson's disease. Lancet 373: 2055-2066.
38. Lewis SJ, Slabosz A, Robbins TW, Barker RA, Owen AM (2005). Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 43: 823-832.
39. Madden GJ, Bickel WK, Jacobs EA (1999). Discounting of delayed rewards in opioid-dependent outpatients: exponential or hyperbolic discounting functions? Exp Clin Psychopharmacol 7: 284-293.
40. Mason O, Linney Y, Claridge G (2005). Short scales for measuring schizotypy. Schizophr Res 78: 293-296.
41. Mitchell SH (1999). Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology (Berl) 146: 455-464.
42. Mobini S, Body S, Ho MY, Bradshaw CM, Szabadi E, Deakin JF et al (2002). Effects of lesions of the orbitofrontal cortex on sensitivity to delayed and probabilistic reinforcement. Psycho-pharmacology (Berl) 160: 290-298.
43. Myerson J, Green L (1995). Discounting of delayed rewards: models of individual choice. J Exp Anal Behav 64: 263-276.
44. Odum AL, Madden GJ, Bickel WK (2002). Discounting of delayed health gains and losses by current, never- and ex-smokers of cigarettes. Nicotine Tob Res 4: 295-303.
45. Ondo WG, Lai D (2008). Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 14: 28-32.
46. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP et al (1992). Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115(Part 6): 1727-1751.
47. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD (2006). Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 442: 1042-1045.
48. Peterson DA, Elliott C, Song DD, Makeig S, Sejnowski TJ, Poizner H (2009). Probabilistic reversal learning is impaired in Parkinson's disease. Neuroscience 163: 1092-1101.
49. Petry NM (2001). Delay discounting of money and alcohol in actively using alcoholics, currently abstinent alcoholics, and controls. Psychopharmacology (Berl) 154: 243-250.
50. Petry NM (2002). Discounting of delayed rewards in substance abusers: relationship to antisocial personality disorder. Psycho-pharmacology (Berl) 162: 425-432.
51. Pine A, Seymour B, Roiser JP, Bossaerts P, Friston KJ, Curran HV et al (2009). Encoding of marginal utility across time in the human brain. J Neurosci 29: 9575-9581.
52. Pleger B, Ruff CC, Blankenburg F, Kloppel S, Driver J, Dolan RJ (2009). Influence of dopaminergically mediated reward on somatosensory decision-making. PLoS Biol 7: e1000164.
53. Potenza MN, Voon V, Weintraub D (2007). Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 3: 664-672.
54. Rachlin H, Raineri A, Cross D (1991). Subjective probability and delay. J Exp Anal Behav 55: 233-244.
55. Rescorla RA, Wagner AR (1972). A theory of Pavlovian conditioning: variations in the effectiveness of reinforcement and nonreinforcement. In: Black AH, Prokasy WF (eds). Classical conditioning II: Current Research and Theory. Appelton-Century-Crofts: New York. pp 64-99.
56. Roesch MR, Calu DJ, Burke KA, Schoenbaum G (2007). Should I stay or should I go? Transformation of time-discounted rewards in orbitofrontal cortex and associated brain circuits. Ann NY Acad Sci 1104: 21-34.
57. Roiser JP, Stephan KE, den Ouden HE, Barnes TR, Friston KJ, Joyce EM (2009). Do patients with schizophrenia exhibit aberrant salience? Psychol Med 39: 199-209.
58. Rossi M, Gerschcovich ER, de Achaval D, Perez-Lloret S, Cerquetti D, Cammarota A et al (2010). Decision-making in Parkinson's disease patients with and without pathological gambling. Eur J Neurol 17: 97-102.
59. Rutledge RB, Lazzaro SC, Lau B, Myers CE, Gluck MA, Glimcher PW (2009). Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task. J Neurosci 29: 15104-15114.
60. Sawaguchi T, Goldman-Rakic PS (1994). The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neuro-physiol 71: 515-528.
61. Schmidt K, Roiser JP (2009). Assessing the construct validity of aberrant salience. Front Behav Neurosci 3: 58.
62. Schultz W, Dayan P, Montague PR (1997). A neural substrate of prediction and reward. Science 275: 1593-1599.
63. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33; quiz 34-57.
64. Spielberger CD, Gorsuch RL, Lushene RE (1970). Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA.
65. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T et al (2009). Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132: 1376-1385.
66. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW (2000). Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 38: 596-612.
67. Tamminga CA, Nestler EJ (2006). Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry 163: 180-181.
68. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH (2007). Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 68: 301-303.
69. Van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP (2009). Dopamine agonists diminish value sensiti- vity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology 34: 2758-2766.
70. Van Eimeren T, Siebner HR (2006). An update on functional neuroimaging of parkinsonism and dystonia. Curr Opin Neurol 19: 412-419.
71. Voon V, Fox SH (2007). Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64: 1089-1096. (Pubitemid 47258066)
72. Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, Ekanayake V et al (2010). Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl) 207: 645-659.
73. Wade TR, de Wit H, Richards JB (2000). Effects of dopaminergic drugs on delayed reward as a measure of impulsive behavior in rats. Psychopharmacology (Berl) 150: 90-101.
74. Wechsler D (1981). Wechsler Adult Intelligence ScaleFRevised. The Psychological Corporation: New York.
75. Wechsler D (2001). Wechsler Test of Adult Reading Manual. The Psychological Cooperation: San Antonio, TX.
76. Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572-575.
77. Winstanley CA, Theobald DE, Dalley JW, Cardinal RN, Robbins TW (2006). Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal and orbitofrontal cortex during a test of impulsive choice. Cereb Cortex 16: 106-114.
78. Wyvell CL, Berridge KC (2000). Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward 'wanting' without enhanced 'liking' or response reinforcement. J Neurosci 20: 8122-8130.
79. Zahrt J, Taylor JR, Mathew RG, Arnsten AF (1997). Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17: 8528-8535.
80. Ziauddeen H, Murray GK (2010). The relevance of reward pathways for schizophrenia. Curr Opin Psychiatry 23: 91-96.